StreetInsider.com News Articles

Cantor Fitzgerald Starts Sagimet Biosciences Inc (SGMT) at Overweight

Wed, 09 Sep 2026 06:13:07 -0400

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences Inc (NASDAQ: SGMT) with a Overweight rating.

For an analyst ratings summary and ratings history on Sagimet Biosciences Inc click here. For more ratings news on Sagimet Biosciences Inc click here.

Shares of Sagimet Biosciences Inc closed at $10.71 yesterday.

Barclays Upgrades Sagimet Biosciences Inc (SGMT) to Overweight

Wed, 09 Sep 2026 03:19:57 -0400

Barclays analyst Eliana Merle upgraded Sagimet Biosciences Inc (NASDAQ: SGMT) from Equalweight to Overweight with a price target of $18.00 (from $8.00).

The analyst comments: “We recently caught up with SGMT. We increase our price target to $18 from $8 and upgrade to an Overweight rating from Equal Weight as we increase credit to acne and update our estimates after model review. We think at an EV of ~$400M (~$750M cap 9/8, ~$250M cash exiting 2Q) SGMT shares underprice the opportunity for defanistat as a safe oral in acne where we see a large market with limited novel mechanisms approved—we est

Barclays Upgrades Sagimet Biosciences Inc (SGMT) to Overweight

Wed, 09 Sep 2026 03:19:57 -0400

Barclays analyst Eliana Merle upgraded Sagimet Biosciences Inc (NASDAQ: SGMT) from Equalweight to Overweight with a price target of $18.00 (from $8.00).

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.

Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).
H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026.

The fireside chat will be available in the Investors & Media section of

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).
H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026.

The fireside chat will be available in the Investors & Media section of

Sagimet targets Q4 2026 enrollment for acne drug trial

Tue, 25 Aug 2026 07:00:13 -0400

Sagimet Biosciences Inc. (NASDAQ: SGMT) announced that its AURORA Phase 3 clinical trial of denifanstat, a FASN inhibitor being studied for moderate to severe acne, is on track to begin patient enrollment in the fourth quarter of 2026, according to a company statement.

The Foster City, California-based company said all clinical trial sites have been identified and a contract research organization (CRO) has been retained. Patient screening is expected to begin in October 2026, with the first patient enrollment to follow shortly after.

The trial is designed to enroll approximately 800 U.S. patients aged 12 and older, including approximately 450 adolescents between

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

Tue, 25 Aug 2026 07:00:00 -0400

All clinical trial sites identified and CRO retained

Patient screening expected to begin in October 2026,
with first patient to be enrolled shortly after

FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026.

"We continue to advance the clinical development of denifanstat for acne and remain on

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

Tue, 25 Aug 2026 07:00:00 -0400

All clinical trial sites identified and CRO retained

Patient screening expected to begin in October 2026,
with first patient to be enrolled shortly after

"We continue to advance the clinical development of denifanstat for acne and remain on

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:28:00 -0400

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:28:00 -0400

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:28:00 -0400

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:28:00 -0400

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation

Form 4 Sagimet Biosciences Inc. For: Aug 14 Filed by: Kemble George

Mon, 17 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26937940.html

Form 4 Sagimet Biosciences Inc. For: Aug 14 Filed by: Kemble George

Mon, 17 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26937940.html

Form 144 Sagimet Biosciences Inc. Filed by: Kemble George

Fri, 14 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26931774.html

Form 144 Sagimet Biosciences Inc. Filed by: Kemble George

Fri, 14 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26931774.html

Form SCHEDULE 13G Sagimet Biosciences Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924138.html

Form SCHEDULE 13G Sagimet Biosciences Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924138.html

Sagimet Biosciences (SGMT) PT Raised to $29 at Citizens on Denifanstat Peak Sales Estimate

Fri, 14 Aug 2026 04:22:14 -0400

Citizens analyst Jonathan Wolleben raised the price target on Sagimet Biosciences Inc (NASDAQ: SGMT) to $29.00 (from $12.00) while maintaining a Market Outperform rating.

The analyst commented, "Ahead of the 52-week Phase 3 data from partner Ascletis coming at EADV, we are raising our POS and peak sales estimate for denifanstat, which could be the first innovative acne treatment in decades; we reiterate our Market Outperform rating and raise our risk-adjusted, DCF-derived price target to $29 from $12...We know the 52-week data will look good with Ascletis saying that all efficacy endpoints improved from the 12-week double-blind portion. The open-label nature

Sagimet Biosciences (SGMT) PT Raised to $29 at Citizens on Denifanstat Peak Sales Estimate

Fri, 14 Aug 2026 04:22:14 -0400

Citizens analyst Jonathan Wolleben raised the price target on Sagimet Biosciences Inc (NASDAQ: SGMT) to $29.00 (from $12.00) while maintaining a Market Outperform rating.

Form 8-K Sagimet Biosciences Inc. For: Aug 13

Thu, 13 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26916299.html

Form 8-K Sagimet Biosciences Inc. For: Aug 13

Thu, 13 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26916299.html

Sagimet gets FDA clearance for phase 3 acne trial of denifanstat

Thu, 13 Aug 2026 07:00:18 -0400

Sagimet Biosciences Inc. (NASDAQ: SGMT) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application and issued a "Study May Proceed" letter for a Phase 3 clinical trial of denifanstat in moderate to severe acne.

The multi-center, randomized, double-blind, placebo-controlled trial is designed to enroll approximately 800 U.S. patients aged 12 and older, with 450 expected to be adolescents between the ages of 12 and 17. Patients will be randomized 2:1 to receive denifanstat 50 mg or placebo once daily for 12 weeks. The trial has three co-primary endpoints assessed at week 12: the proportion

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Thu, 13 Aug 2026 07:00:00 -0400

Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026

FOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application and issued a “Study May Proceed” letter for the company’s Phase 3 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat in moderate to severe acne. The Phase 3

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Thu, 13 Aug 2026 07:00:00 -0400

Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026